Literature DB >> 22754607

S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase.

Joel A Bergman1, Kalub Hahne, Jiao Song, Christine A Hrycyna, Richard A Gibbs.   

Abstract

We report the design and synthesis of novel FTPA-triazole compounds as potent inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt), through a focus on thioether and isoprenoid mimetics. These mimetics were coupled utilizing a copper-assisted cycloaddition to assemble the potential inhibitors. Using the resulting triazole from the coupling as an isoprenyl mimetic resulted in the biphenyl substituted FTPA triazole 10n. This lipid-modified analog is a potent inhibitor of Icmt (IC(50) = 0.8 ± 0.1 μM; calculated K(i) = 0.4 μM).

Entities:  

Year:  2011        PMID: 22754607      PMCID: PMC3387282          DOI: 10.1021/ml200106d

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

1.  Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases.

Authors:  David Michaelson; Wasif Ali; Vi K Chiu; Martin Bergo; Joseph Silletti; Latasha Wright; Stephen G Young; Mark Philips
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

2.  The isoprenoid substrate specificity of isoprenylcysteine carboxylmethyltransferase: development of novel inhibitors.

Authors:  Jessica L Anderson; Brian S Henriksen; Richard A Gibbs; Christine A Hrycyna
Journal:  J Biol Chem       Date:  2005-06-09       Impact factor: 5.157

3.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Authors:  Anurag Singh; Patricia Greninger; Daniel Rhodes; Louise Koopman; Sheila Violette; Nabeel Bardeesy; Jeff Settleman
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

4.  Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells.

Authors:  M O Bergo; G K Leung; P Ambroziak; J C Otto; P J Casey; S G Young
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

Review 5.  Lipid posttranslational modifications. Farnesyl transferase inhibitors.

Authors:  Andrea D Basso; Paul Kirschmeier; W Robert Bishop
Journal:  J Lipid Res       Date:  2005-11-08       Impact factor: 5.922

6.  Yeast STE14 methyltransferase, expressed as TrpE-STE14 fusion protein in Escherichia coli, for in vitro carboxylmethylation of prenylated polypeptides.

Authors:  C A Hrycyna; S J Wait; P S Backlund; S Michaelis
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

7.  Farnesylcysteine analogs to probe role of prenylated protein methyltransferase.

Authors:  Y T Ma; B A Gilbert; R R Rando
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

8.  Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation.

Authors:  A Paz; R Haklai; G Elad-Sfadia; E Ballan; Y Kloog
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

9.  Enantioselective synthesis of (-)-terpestacin and structural revision of siccanol using catalytic stereoselective fragment couplings and macrocyclizations.

Authors:  Johann Chan; Timothy F Jamison
Journal:  J Am Chem Soc       Date:  2004-09-01       Impact factor: 15.419

10.  Identifying the recognition unit for G protein methylation.

Authors:  E W Tan; D Pérez-Sala; F J Cañada; R R Rando
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

View more
  13 in total

1.  Exploration of GGTase-I substrate requirements. Part 1: Synthesis and biochemical evaluation of novel aryl-modified geranylgeranyl diphosphate analogs.

Authors:  Kayla J Temple; Elia N Wright; Carol A Fierke; Richard A Gibbs
Journal:  Bioorg Med Chem Lett       Date:  2016-06-16       Impact factor: 2.823

Review 2.  Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation.

Authors:  Hiu Yeung Lau; Mei Wang
Journal:  Small GTPases       Date:  2018-01-25

3.  Isoprenylcysteine carboxyl methyltransferase is critical for glioblastoma growth and survival by activating Ras/Raf/Mek/Erk.

Authors:  Weifeng Wan; Wenfeng Xiao; Wen Pan; Ligang Chen; Zhiyong Liu; Jianguo Xu
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-16       Impact factor: 3.333

4.  Non-Substrate Based, Small Molecule Inhibitors of the Human Isoprenylcysteine Carboxyl Methyltransferase.

Authors:  Kyle V Butler; Kelsey Bohn; Christine A Hrycyna; Jian Jin
Journal:  Medchemcomm       Date:  2016-04-14       Impact factor: 3.597

Review 5.  Protein prenylation: unique fats make their mark on biology.

Authors:  Mei Wang; Patrick J Casey
Journal:  Nat Rev Mol Cell Biol       Date:  2016-01-21       Impact factor: 94.444

6.  Synthesis of Farnesol Analogues Containing Triazoles in Place of Isoprenes through 'Click Chemistry'

Authors:  Thangaiah Subramanian; Sean Parkin; H Peter Spielmann
Journal:  Synlett       Date:  2012-10       Impact factor: 2.454

7.  Triazole-based inhibitors of geranylgeranyltransferase II.

Authors:  Xiang Zhou; Sara V Hartman; Ella J Born; Jacqueline P Smits; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2012-12-01       Impact factor: 2.823

Review 8.  Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease.

Authors:  Angela Jeong; Kiall Francis Suazo; W Gibson Wood; Mark D Distefano; Ling Li
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-06       Impact factor: 8.250

Review 9.  Catalytic enantioselective synthesis of chiral organic compounds of ultra-high purity of >99% ee.

Authors:  Ei-ichi Negishi; Shiqing Xu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2015       Impact factor: 3.493

Review 10.  Post-translational modification of KRAS: potential targets for cancer therapy.

Authors:  Wei-Hua Wang; Tao Yuan; Mei-Jia Qian; Fang-Jie Yan; Liu Yang; Qiao-Jun He; Bo Yang; Jin-Jian Lu; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-10-21       Impact factor: 7.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.